Deloitte and Thomson Reuters recently performed their annual R&D-ROI balance by assessing the finances of the top 12 life sciences companies. The study reports a mixed performance picture in 2012 relative to the previous year. More drugs were approved between 2011 and 2012, yet the total sales value of all approvals has declined compared to the 2010-11 time period. Revenue lost from failed projects still remains a challenge for the assessed companies; however, the proposed solutions include repositioning or repurposing the failed compounds to recoup losses. To read the major findings of the study, click here. For the complete Deloitte and Thomson Reuters report, click here.